AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15451336
Drug: Mifepristone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone and misoprostol (misoprostol administered 6-8 hours vs. 23-25 hours after mifepristone)
Trial: 11553119
Drug: Household cleansing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Household cleansing solutions adjusted to pH 7.4
Trial: 11553119
Drug: Household cleansing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Household cleansing solutions adjusted to pH 10.0
Trial: 11553119
Drug: Household cleansing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Household cleansing solutions adjusted to pH 10.8
Trial: 8014642
Drug: Fixed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed low-dose warfarin (2 mg/d)
Trial: 8014642
Drug: Adjusted higher-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted higher-dose warfarin
Trial: 2685260
Drug: Radiographic assessments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiographic assessments of implants
Trial: 26481821
Drug: Ranibizumab 0.3
RxNorm normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.3 mg monthly (frequent regimen; n = 102)
Trial: 26481821
Drug: Ranibizumab 0.3
RxNorm normalized name: RANIBIZUMAB 0.3MG/0.05ML INJ,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.3 or 0.5 mg quarterly (infrequent regimen; n = 217)
Trial: 24344871
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of reading acceleration and WM training
Trial: 22431170
Drug: Goserelin (GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (GnRH agonist)
Trial: 22431170
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (Bicalutamide and Goserelin)
Trial: 15502600
Drug: d,l‐MPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l‐MPH
Trial: 9540946
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg linoleic acid and 600 mg calcium
Trial: 9540946
Drug: 450 mg
RxNorm normalized name: aspirin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 mg starch and 600 mg lactose placebo
Trial: 28679020
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg administered with food (evening meal for AF, morning meal for DVT)
Trial: 28679020
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg administered with food
Trial: 28679020
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg administered with evening meal (AF population)
Trial: 28679020
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg administered with morning meal (DVT population)
Trial: 25034935
Drug: S(+)‐ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(+)‐ketamine 0.5 mg.kg‐1 (S+K group)
Trial: 25034935
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine 1.5 mg.kg‐1 (L5% group)
Trial: 25034935
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline 3 ml (SF group; control group)
Trial: 24151326
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of 25 to 30 minutes of aerobic exercise (STAN)
Trial: 24151326
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of 50 to 60 minutes of aerobic exercise (HIGH)
Trial: 24151326
Drug: Combined dose
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined dose of 50 to 60 minutes of aerobic and resistance exercise (COMB)
Trial: 21218090
Drug: Ginger (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (1.2 g)
Trial: 19388899
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg hyperbaric bupivacaine
Trial: 19388899
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg hyperbaric bupivacaine with 15 microg of clonidine
Trial: 14985138
Drug: 0.17 l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.17 l of water every 1/2 hour
Trial: 14985138
Drug: 0.6 l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 l of water every 1/2 hour
Trial: 7506174
Drug: nimesulide (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide (50mg twice daily)
Trial: 18379535
Drug: Icodextrin solution
RxNorm normalized name: icodextrin Irrigation Solution
DrugBank: Icodextrin (DB00702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Icodextrin solution
Trial: 27043667
Drug: 1.5% glucose-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% glucose-based biocompatible neutral pH solution
Trial: 19439284
Drug: Uterine cavity
RxNorm normalized name: gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uterine cavity injection of day 2 embryo culture supernatant before day 3 embryo transfer
Trial: 18308656
Drug: Basal-bolus insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-bolus insulin regimen (0.5 U/kg total daily dose: 0.25 U/kg insulin glargine and 0.25 U/kg divided into 3 mealtime doses)
Trial: 15026400
Drug: Iontophoretic fentanyl
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Iontophoretic fentanyl hydrochloride (40-microg infusion over 10 minutes)
Trial: 15026400
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine (1-mg bolus every 5 minutes; maximum of 10 mg/h)
Trial: 11393871
Drug: Prison-based residential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prison-based residential drug treatment
Trial: 26941050
Drug: ECIG with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECIG with 0 mg/ml nicotine concentration
Trial: 26941050
Drug: ECIG with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECIG with 8 mg/ml nicotine concentration
Trial: 26941050
Drug: ECIG with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECIG with 36 mg/ml nicotine concentration
Trial: 26941050
Drug: All ECIG
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All ECIG conditions (0, 8, 36 mg/ml)
Trial: 10772502
Drug: Intravenous aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminophylline 500 mg administered 45 minutes prior to SWL
Trial: 3537248
Drug: Vaccine virus
RxNorm normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine virus at 10(7) TCID50/ml
Trial: 3537248
Drug: Vaccine virus
RxNorm normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine virus at 10(8) TCID50/ml
Trial: 3537248
Drug: Both vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccine groups (10(7) and 10(8) TCID50/ml)
Trial: 27992863
Drug: Statin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin plus fenofibrate treatment in patients without CKD
Trial: 27992863
Drug: Statin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin plus fenofibrate treatment in patients with CKD
Trial: 25611084
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg QW plus topical therapies
Trial: 23224792
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg once a day, rabeprazole 20 mg twice a day, and tinidazole 500 mg twice daily for 7 days followed by rabeprazole 20 mg OD for 8 weeks
Trial: 18495885
Drug: Glutamate antagonists
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate antagonists (caroverine and ketamine) administered during sleep
Trial: 9170519
Drug: Low-dose MPA
RxNorm normalized name: chitosan low molecular weight (20-200 MPA.S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose MPA (600 mg/day)
Trial: 9170519
Drug: High-dose MPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose MPA (1,200 mg/day)
Trial: 8253229
Drug: Intermittent pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent pilocarpine drop medication (2%)
Trial: 8253229
Drug: Continuous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous low-dose pilocarpine delivery by a membrane-controlled Ocusert unit (P40)
Trial: 31324831
Drug: Dobutamine (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (5, 10, 20 μg/kg.min)
Trial: 29068453
Drug: SFA high‐fat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFA high‐fat meal with orange juice (500 ml)
Trial: 29068453
Drug: MUFA high‐fat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MUFA high‐fat meal with orange juice (500 ml)
Trial: 22994024
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 2 ml (Group I)
Trial: 22994024
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg (Group II)
Trial: 22994024
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg (Group III)
Trial: 10929726
Drug: Standardized pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized pain therapy with tramadol and diclofenac
Trial: 10929726
Drug: No standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No standardized pain therapy
Trial: 8523873
Drug: Duraflo II
RxNorm normalized name: Duraflor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duraflo II heparin-treated circuits
Trial: 1742223
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folinic acid (FA) + 5-fluorouracil (5-FU) (200 mg/sqm i.v. x 5 days + 400 mg/sqm i.v. in 15' x 5 days every 4 weeks)
Trial: 1742223
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) alone (400 mg/sqm i.v. in 15' x 5 days every 4 weeks)
Trial: 6972018
Drug: Triple sulfa
RxNorm normalized name: Triple Sulfa
DrugBank: Sulfabenzamide (DB09355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple sulfa cream
Trial: 26304886
Drug: Lenalidomide alone
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide alone (15 mg per day on days 1 to 21, followed by 7 days of rest in cycle 1; then 20 mg per day on days 1 to 21, followed by 7 days of rest in cycles 2 to 12)
Trial: 26304886
Drug: Lenalidomide plus
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide plus Rituximab (LR) (Rituximab 375 mg/m2 weekly for 4 weeks; Lenalidomide as above)
Trial: 15562056
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine 1.5 mg/kg
Trial: 11352682
Drug: Serum elastin
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum elastin peptides (EP) and procollagen‐IIIN‐terminal propeptide (PIIINP) measured in ng/ml using ELISA and RIA techniques.
Trial: 9135021
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy with 5-fluorouracil plus levamisole
Trial: 7523647
Drug: Iron-fortified formula
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified formula (12.8 mg iron per liter)
Trial: 7523647
Drug: Regular formula
RxNorm normalized name: COMPLEAT REGULAR FORMULA LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular formula (1.1 mg iron per liter)
Trial: 31836609
Drug: Capivasertib 480
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib 480 mg b.i.d.
Trial: 31836609
Drug: Capivasertib 360
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib 360 mg b.i.d.
Trial: 31836609
Drug: Capivasertib 240
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib 240 mg b.i.d.
Trial: 17132769
Drug: Daily sunscreen
RxNorm normalized name: ZINC OXIDE 220 mg in 1 mL TOPICAL CREAM [SPF 30 Daily Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sunscreen use
Trial: 12843357
Drug: Common haplotype
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common haplotype A-G-8/12-C
Trial: 10068383
Drug: CEE plus
RxNorm normalized name: Ecee Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE plus daily MPA
Trial: 1704026
Drug: Cold glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold glucose solution (5 degrees C)
Trial: 1704026
Drug: Warm glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm glucose solution (50 degrees C)
Trial: 6660202
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of Reha of the lesion with acupuncture on the abnormal side (including points Chu‐chih (LI‐11), Shou‐san‐li (LI‐10), Wai‐kuan (TH‐5), Ho‐ku (LI‐4), Yang‐chih (TH‐4)).
Trial: 6660202
Drug: Simple treatment
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple treatment with Reha on the abnormal side.
Trial: 6660202
Drug: Simple treatment
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple treatment with acupuncture on the abnormal side.
Trial: 30037491
Drug: CPT‐11 (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT‐11 (irinotecan hydrochloride) administered at a dosage of 100 mg/m2 via intravenous infusion on days 1, 8, and 15 of a 4-week cycle, for up to 2 cycles.
Trial: 22433300
Drug: Flurbiprofen 8.75-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 8.75-mg lozenges (test drug)
Trial: 22433300
Drug: Flurbiprofen 8.75-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 8.75-mg lozenges (reference drug)
Trial: 20694731
Drug: Cooling collar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling collar (CC(90))
Trial: 20694731
Drug: Cooling collar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling collar (CC(15))
Trial: 17987285
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg once on the first day and 200 mg once on the second day)
Trial: 17987285
Drug: Control (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (5 microg/kg of intravenous fentanyl without pretreatment)
Trial: 12391036
Drug: Coffee ingestion
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee ingestion (5 mg caffeine/kg body mass)
Trial: 9135468
Drug: Oral metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoclopramide administered 90 min prior to barium
Trial: 1398229
Drug: Psyllium (10.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium (10.8 g)
Trial: 22633178
Drug: Educational and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Educational and environmental intervention (weekly nutrition and food classes and food environment changes)
Trial: 20045366
Drug: Miglustat (Zavesca)
RxNorm normalized name: Miglustat
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Miglustat (Zavesca) for >or= 1 dose
Trial: 15974563
Drug: etoricoxib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etoricoxib (60 mg, 90 mg, or 120 mg)
Trial: 15974563
Drug: non-selective NSAIDs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-selective NSAIDs (ibuprofen, diclofenac, or naproxen)
Trial: 11379456
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of the TSI-GSD 200 vaccine
Trial: 11379456
Drug: One or
RxNorm normalized name: Geone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or two doses of the TSI-GSD 200 vaccine
Trial: 1531259
Drug: Phloroglucinol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phloroglucinol (40 mg, two ampoules)
Trial: 31489020
Drug: Oral Labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Labetalol
Trial: 31489020
Drug: Oral Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Nifedipine
Trial: 24778393
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 mg on days 1 to 14; 200 mg on days 15 to 28)
Trial: 20086031
Drug: Linagliptin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin (10 mg, oral)
Trial: 20086031
Drug: Linagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin (5 mg, intravenous)
Trial: 18955380
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of iron
Trial: 18955380
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of desferrioxamine
Trial: 15468991
Drug: L-sulpiride (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-sulpiride (25 mg t.i.d. intravenously for 3 days, then orally for 7 days)
Trial: 8310852
Drug: L-sulpiride
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-sulpiride
Trial: 7663466
Drug: Implant design,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant design, application, and site of placement
Trial: 3604933
Drug: Sonicated Renografin‐76
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonicated Renografin‐76 (1.5 to 2.0 ml)
Trial: 3604933
Drug: Nonsonicated Renografin‐76
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsonicated Renografin‐76 (7 to 9 ml)
Trial: 25246774
Drug: Aminaphtone (Capilarema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminaphtone (Capilarema 75 mg) administered twice daily for 5 days
Trial: 25246774
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily for 5 days
Trial: 22047100
Drug: Errorless naming
RxNorm normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Errorless naming treatment (ENT)
Trial: 19283886
Drug: HP-L (High
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-L (High Protein at Lunch)
Trial: 17375492
Drug: Intervention dose
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention dose (number of six possible intervention components completed)
Trial: 11916546
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m(2) on day 1) plus 5-fluorouracil (1000 mg/m(2) continuous infusion for 4 days)
Trial: 11916546
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m(2) on day 1) plus 5-fluorouracil (1000 mg/m(2) continuous infusion for 4 days) plus alpha-interferon 2b (3 million Units/day subcutaneously from day 1 for 5 days)
Trial: 7630152
Drug: Ibopamine 100
RxNorm normalized name: ibopamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine 100 mg orally (p.o.)
Trial: 2705719
Drug: PTFE (Gore‐tex,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTFE (Gore‐tex, W L Gore)
Trial: 937355
Drug: Meperidine hydrochloride
RxNorm normalized name: Meperidine Hydrochloride
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine hydrochloride 100 mg
Trial: 937355
Drug: Pentazocine 60
RxNorm normalized name: pentazocine 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine 60 mg
Trial: 25299740
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel filler augmentation of the tear trough
Trial: 25299740
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel augmentation of the cheek
Trial: 11532487
Drug: Intergel solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intergel solution (300 mL)